Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086541 | 0.98 | OPRD1 (0.47) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL11253408 | 0.98 | OPRD1 (0.47) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL15021498 | 0.95 | OPRD1 (0.47) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL617985 | 0.95 | OPRD1 (0.47) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL619743 | 0.93 | OPRD1 (0.46) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL617209 | 0.85 | OPRD1 (0.44) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| Trifluoroacetic Acid SCHEMBL619745 | 0.82 | OPRD1 (0.40) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL4343470 | 0.81 | KMT2A (0.62) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL1115144 | 0.80 | OPRD1 (0.46) | OPRD1KMT2ATRPV1CYP2D6KCNH2 | |
| SCHEMBL12162414 | 0.80 | OPRD1 (0.46) | OPRD1KMT2ATRPV1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598220-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-7622493-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | OPRL1, AVPR1A, TRPV1 | OPRD1 15/4885KMT2A 2351/4885TRPV1 3/4885 |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | OPRL1, AVPR1A, AVPR1B | OPRD1 18/4885KMT2A 2276/4885TRPV1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.